TRIM24 and neoplasm: The PSMAb-mediated TRIM24 siRNA delivery platform demonstrated significant inhibition of cell proliferation, colony formation, and invasion in PSMA-positive CRPC in vitro, and suppression of tumor growth in a xenograft model.